Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell ...

Vir Biotechnology, Inc.: Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically ...

SHORT FORM ANNOUNCEMENT: REVIEWED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 AND UPDATED BUSINESS OUTLOOK

JOHANNESBURG, Feb. 23, 2026 /PRNewswire/ -- Sasol has released its operating and financial results for the six months ended 31 December 2025 (H1 FY26). Turnover of R122,4 billion remained flat ...
Opinion
The Manila Times on MSNOpinion

The ICC hoax: Hard data demolish ‘widespread EJKs’ charge vs Duterte

THE International Criminal Court’s (ICC) case against former president Rodrigo Duterte is an abomination and a huge, horrific hoax. President Ferdinand Marcos Jr. will go down in history as more ...

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 ...